Patent ID: 7776863

Claim:
A method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of at least one other agent, including pharmaceutically acceptable salts thereof, used for treatment of AIDS or HIV infection selected from the group consisting of the nucleoside HIV reverse transcriptase inhibitors didanosine, emtricitabine and zalcitabine, the non-nucleoside HIV reverse transcriptase inhibitors delavirdine and efavirenz, the HIV protease inhibitors ritonavir and saquinavir, and the HIV fusion inhibitor enfuvirtide, wherein the EC 50 ratio of said piperazine compound to said other agent is 1:1, 1:2.5 or 2.5:1.